ASCO 2018 Multiple Myeloma Abstracts –
Oral Presentations
Oral presentations related to multiple myeloma will take place during an afternoon session on Friday, June 1 during the 2018 American Society of Clinical Oncology (ASCO) annual meeting.
The list below contains the titles and authors of all multiple myeloma oral presentations at ASCO 2018. Each entry in the list also includes a link to the full text of the relevant abstract at the ASCO website.
Links to PDF files containing presentation slides will be added to entries in this list as those files are made available to The Beacon courtesy of the ASCO presenters.
Please note that this list does not myeloma-related education session presentations.
The Beacon also has complete lists of all ASCO 2018 multiple myeloma-related poster presentations, education session presentations, and e-abstracts.
| Session | Hematologic Malignancies – Plasma Cell Dyscrasia |
| Type | Oral Abstract Session |
| Time | Friday, June 1, 2:45 PM - 5:45 PM |
| Location | E450 |
8000 - Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.
Maria-Victoria Mateos, Philippe Moreau, James R. Berenson, Katja Weisel, Antonio Lazzaro, Kevin W. Song, Meletios A. Dimopoulos, Mei Huang, Anita Zahlten-Kumeli, A. Keith Stewart (abstract; presentation slides [PDF] courtesy of Dr. Mateos)
8001 - Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial
Paul G. Richardson, Albert Oriol Rocafiguera, Meral Beksac, Anna Marina Liberati, Monica Galli, Fredrik Schjesvold, Jindriska Lindsay, Katja Weisel, Darell White, Thierry Facon, Jesus San-Miguel, Kazutaka Sunami, Peter O'Gorman, Pieter Sonneveld, Xin Yu, Thomas Doerr, Amine Bensmaine, Mohamed H. Zaki, Kenneth Carl Anderson, Meletios A. Dimopoulos (abstract)
8002 - Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001
Ajai Chari, Joaquin Martinez-Lopez, Maria-Victoria Mateos, Joan Blade, Sagar Lonial, Lotfi Benboubker, Albert Oriol Rocafiguera, Bertrand Arnulf, Jesus San-Miguel, Luis Pineiro, Andrzej J. Jakubowiak, Carla De Boer, Jianping Wang, Jordan Mark Schecter, Philippe Moreau (abstract; presentation slides [PDF] courtesy of Dr. Chari)
Discussion - Abstracts 8000, 8001, and 8002
David Samuel DiCapua Siegel, MD, PhD
8004 - Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Luciano J. Costa, Edward Allen Stadtmauer, Gareth John Morgan, Gregory P. Monohan, Tibor Kovacsovics, Nicholas Burwick, Andrzej J. Jakubowiak, Mehrdad Mobasher, Kevin Freise, Jeremy A. Ross, John Carl Pesko, Wijith Munasinghe, Jaclyn Cordero, Lura Morris, Paulo Cesar Maciag, Orlando Bueno, Shaji Kumar (abstract; presentation slides [PDF] courtesy of Dr. Costa)
8005 - A phase 1 trial of ruxolitinib, lenalidomide, and methylprednisolone for relapsed/refractory multiple myeloma patients
James R. Berenson, Jennifer To, Tanya M. Spektor, Carley Turner, Regina A. Swift, Benjamin M Eades, Gary Schwartz, Shahrooz Eshaghian, Laura Stampleman, Robert A. Moss, Stephen Lim, Robert A. Vescio (abstract)
Discussion - Abstracts 8004 and 8005
Craig C. Hofmeister, MD, MPH (presentation slides [PDF] courtesy of Dr. Hofmeister)
8006 - Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma.
Nina Shah, Rohtesh Mehta, Li Li, Jessica Mccarty, Indreshpal Kaur, Robert Z. Orlowski, Laurence Cooper, Dean Anthony Lee, Kai Cao, Simrit Parmar, Chitra Hosing, Sairah Ahmed, Yago Nieto, Qaiser Bashir, Krina K. Patel, Catherine Bollard, Muzaffar H. Qazilbash, Richard E. Champlin, Katayoun Rezvani, Elizabeth J. Shpall (abstract; presentation slides [PDF] courtesy of Dr. Shah)
8007 - bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study
Noopur S. Raje, Jesus G. Berdeja, Yi Lin, Nikhil C. Munshi, David Samuel DiCapua Siegel, Michaela Liedtke, Sundar Jagannath, Deepu Madduri, Jacalyn Rosenblatt, Marcela Valderrama Maus, Ashley Turka, Lyh Ping Lam, Richard A. Morgan, Travis Quigley, Monica Massaro, Kristen Hege, Fabio Petrocca, James Kochenderfer (abstract; presentation slides [PDF] courtesy of Dr. Raje)
8008 - FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response
Aviva C Krauss, Flora Mulkey, Yuan-Li Shen, Amy Rosenberg, Barry Miller, Theresa Carioti, Kimberly Scott, Nicole Gormley, Marc Robert Theoret, Rajeshwari Sridhara, Ann T. Farrell, Richard Pazdur, MD (abstract)
Discussion - Abstracts 8006, 8007, and 8008
Parameswaran Hari, MD (presentation slides [PDF] courtesy of Dr. Hari)
